2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
C. Ola Landgren, MD, PhD, chief of Myeloma Service at Memorial Sloan Kettering Cancer Center, discusses managing toxicities associated with multiple myeloma treatment.
C. Ola Landgren, MD, PhD, chief of Myeloma Service at Memorial Sloan Kettering Cancer Center, discusses managing toxicities associated with multiple myeloma treatment.
While every drug has its own levels of efficacy and toxicity, Landgren says management of toxicities in multiple myeloma treatment comes down to oral clinical exam, monitoring labs and being aware of the safety profiles of each drug.
Physicians should be informing their patients about side effects throughout treatment, as every case is unique and dosage might need to be altered to suit the individual needs of a given patient.
Related Content: